Catalog No.
Product Name
Application
Product Information
Citations
-
PPAR Activator
Bilobetin acts as a PPARα activator, enhancing lipid metabolism and insulin sensitivity. It effectively reduces blood lipid levels by promoting hepatic lipid uptake and oxidation, while decreasing triglyceride secretion and accumulation in tissues. Additionally, Bilobetin stimulates the phosphorylation and nuclear translocation of PPARα, resulting in increased cAMP levels and PKA activity. This compound is significant for research in metabolic disorders, particularly those related to insulin resistance and lipid regulation. -
Glycosaminoglycan
Hyaluronic acid sodium, also known as sodium hyaluronate, is a glycosaminoglycan that plays a crucial role in the extracellular matrix (ECM). This biopolymer is involved in key biological activities such as cell proliferation, tissue remodeling, and angiogenesis, particularly in the context of digestive cancers. Hyaluronic acid sodium is implicated in tumor cell growth and migration, and it activates the PI3K-Akt signaling pathway. This reagent can also be utilized in research related to joint diseases, wound healing, and as a drug delivery system to enhance the efficacy of therapeutics in cancer research. -
TIGIT/PVR Blocker
Liothyronine is an active form of thyroid hormone that primarily targets thyroid hormone receptors TRα and TRβ. It exhibits binding affinities of 2.33 nM and 2.29 nM for human TRα and TRβ, respectively. In addition, Liothyronine binds to PVR and effectively inhibits the interaction between TIGIT and PVR. This compound is useful in research applications related to thyroid hormone signaling and immune modulation studies. -
mtTrxR2 Probe
Mito-TRFS is an innovative off-on probe designed to selectively image mitochondrial thioredoxin reductase (TrxR2) in live cells. This reagent allows for the assessment of the redox status within mitochondria, facilitating the study of oxidative stress and mitochondrial function. Mito-TRFS is particularly valuable in research focusing on cellular responses to stress and the roles of TrxR2 in various disease models. -
Carbonic Anhydrase Inhibitor
Methazolamide is an orally active inhibitor of carbonic anhydrase, demonstrating a Ki of 14 nM for human carbonic anhydrase II. This compound effectively reduces intraocular pressure and exhibits neuroprotective properties, including the ability to inhibit neuronal apoptosis. Methazolamide is applicable in research concerning ophthalmic diseases, such as glaucoma, and cerebrovascular conditions, including subarachnoid hemorrhage. -
COX2 Inhibitor
Iminostilbene is a well-characterized inhibitor of COX2 (Cyclooxygenase-2) with additional activity against PKM2 (Pyruvate Kinase M2). This compound effectively reduces the expression of COX2 and iNOS, as well as the release of pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α, and MCP-1 in macrophages. Its ability to mitigate macrophage-mediated inflammatory responses makes iminostilbene a valuable reagent for investigating mechanisms of inflammation regulation, cardiovascular disease, including myocardial ischemia/reperfusion injury, and immune-related disorders. -
Endogenous Metabolite
Taurochenodeoxycholic acid is an endogenous metabolite primarily involved in bile acid metabolism. It exhibits significant biological activities, including the induction of apoptosis and anti-inflammatory effects, alongside immune regulatory properties. This compound serves as a valuable tool in research applications related to metabolic disorders, inflammation, and immune response studies. -
HO-1 Inducer
Co(III) protoporphyrin IX chloride is a known inducer of heme oxygenase-1 (HO-1). This compound exhibits anti-inflammatory and antibacterial activities, making it valuable in the study of various pathological conditions. It is particularly useful in research involving ischemia-reperfusion injury models, providing insights into potential therapeutic strategies. -
GARFT Inhibitor
Lometrexol, a potent GARFT inhibitor, effectively blocks glycinamide ribonucleotide formyltransferase activity, thereby disrupting de novo purine synthesis. This inhibition leads to abnormal cell proliferation, apoptosis, and potential cell cycle arrest, demonstrating its anticancer properties. Additionally, Lometrexol acts as an inhibitor of human serine hydroxymethyltransferase 1 and 2 (hSHMT1/2), further influencing metabolic processes in cancer research applications. -
HSP90 Inhibitor
Kongensin A is a covalent inhibitor of the heat shock protein 90 (HSP90), isolated from the plant Croton kongensis. This natural product effectively inhibits RIP3-dependent necroptosis while also inducing apoptosis. Kongensin A demonstrates significant potential in research applications focused on necroptosis and inflammation, making it a valuable tool for investigating cellular death pathways and therapeutic strategies. -
AhR Activator
Aminoflavone is an activator of the aryl hydrocarbon receptor (AhR) with significant anti-tumor properties. It modulates the expression of ITGA6/SOX2 through the AhR-miR-125b-2-3p axis, effectively targeting breast cancer stem cells. This compound promotes the generation of reactive oxygen species (ROS) and elevates oxidative DNA damage, as indicated by increased levels of 8-oxodG and DNA-protein cross-links. Additionally, Aminoflavone induces S-phase cell cycle arrest, activates caspase pathways, and triggers apoptosis, while inhibiting HIF-1α expression independent of the AhR pathway. It serves as a valuable reagent for research into breast cancer mechanisms and therapies. -
Endogenous Metabolite
N-Acetyl-L-tryptophan is an antagonist of the neurokinin-1 receptor (NK-1R), effectively disrupting the binding of substance P, which leads to neuroprotective outcomes. This compound is known to improve cognitive function and motor skills while also acting as an inhibitor of cytochrome c, exhibiting antioxidant and anti-inflammatory properties through the regulation of IL-1β expression and caspase-1 activation. N-Acetyl-L-tryptophan is valuable for research investigating neurodegenerative and inflammatory conditions. -
Nampt Inhibitor
OT-82 is a selective, orally active inhibitor of Nicotinamide Adenine Dinucleotide Phosphate (NAMPT). It exhibits potent cytotoxicity specifically towards hematopoietic cells and induces cell death in a NAD+ dependent manner. Due to these properties, OT-82 shows potential as an innovative antineoplastic agent for investigating hematological malignancies. -
Cathepsin B Inhibitor
(Rac)-Z-FA-FMK is a potent inhibitor of cathepsin B, exhibiting a Ki value of 1.5 μM. This compound also inhibits multiple caspases, specifically caspases 2, 3, 6, 7, and 9, with IC50 values ranging from 6.147 to 110.7 μM. Additionally, (Rac)-Z-FA-FMK demonstrates antiviral activity by inhibiting the main protease involved in SARS-CoV-2 replication with an IC50 of 11.39 μM. It further attenuates the increase in IL-1β levels induced by LPS and represses NF-κB transactivation in macrophages, making it useful for research in inflammation and viral pathogenesis. -
Hsp90 Inhibitor
GUT-70 is a tricyclic coumarin that functions as a potent Hsp90 inhibitor. It activates caspases 2, 3, 8, and 9, leading to apoptosis in leukemic cells. Additionally, GUT-70 effectively inhibits HIV-1 replication in chronically infected cells by targeting the NF-κB signaling pathway. This compound is suitable for research applications involving leukemia, mantle cell lymphoma (MCL), and HIV-1 infection studies. -
Apoptosis/Ferroptosis Inducer
Ironomycin is an apoptosis and ferroptosis inducer that targets critical pathways in cancer biology. This compound demonstrates selective inhibitory effects against mantle cell lymphoma (MCL) cells by inducing cell cycle arrest and promoting apoptosis and ferroptosis. Ironomycin causes double-strand DNA breaks and activates the unfolded protein response (UPR), particularly through the IRE1α signaling pathway. The combination of Ironomycin with Ibrutinib yields a synergistic effect, making it a valuable reagent for studying MCL and exploring therapeutic strategies in cancer research. -
PFKFB4 Inhibitor
PFKFB4-IN-1 is a selective ATP-competitive inhibitor of PFKFB4, demonstrating an IC50 of 4.50 μM and over 12-fold selectivity against PFKFB1/4 and PFKFB3/4. This compound effectively reduces intracellular PFKFB4 protein levels and exhibits significant anti-cancer activities, including the inhibition of cell proliferation, induction of apoptosis, and suppression of cell migration. PFKFB4-IN-1 has shown efficacy in vivo, effectively inhibiting tumor growth in the MDA-MB-231 xenograft mouse model, making it a valuable tool for research in breast, lung, and liver cancer. -
Anti-cancer Agent
ME-344 is an isoflavone that functions as an anti-cancer agent, primarily by inhibiting tubulin polymerization and increasing mitochondrial reactive oxygen species (ROS) generation. This compound effectively induces apoptosis through the activation of caspase-3 and inhibits heme oxygenase-1 (HO-1), affecting its mitochondrial translocation. ME-344 exhibits synergistic effects with Vinblastine in leukemia cells and displays significant anti-tumor activity against leukemia and lung tumors. It is a valuable reagent for research on lung cancer, acute myeloid leukemia, and HER2-negative breast cancer. -
PCSK9 Inhibitor
Inclisiran is a double-stranded small interfering RNA (siRNA) that specifically targets and inhibits the transcription of proprotein convertase subtilisin/kexin type 9 (PCSK9). By reducing PCSK9 levels, Inclisiran effectively modulates lipid metabolism and demonstrates anti-inflammatory properties, including the inhibition of pyroptosis and a decrease in NLRP3, cleaved caspase-1, IL-1β, and IL-18. This reagent is valuable for research applications focused on hyperlipidemia and cardiovascular diseases (CVD), as it supports studies aimed at understanding lipid regulation and atherosclerosis. -
15-lipoxygenase Inhibitor
4-MMPB is a selective inhibitor of 15-lipoxygenase, exhibiting an IC50 of 18 μM. It demonstrates competitive inhibition with IC50 values of 19.5 μM for soybean 15-lipoxygenase and 19.1 μM for human 15-lipoxygenase-1. This compound may hold promise for research applications focused on prostate cancer, providing insights into the role of 15-lipoxygenase in tumor biology. -
HMG-CoA Reductase Inhibitor
Pitavastatin sodium is a potent inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase, significantly reducing cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. This compound serves as an effective inducer of low-density lipoprotein-cholesterol (LDL-C) receptors in hepatocytes. In addition to its primary role in cholesterol regulation, pitavastatin sodium exhibits various biological activities, including anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective, and reno-protective effects, making it valuable for diverse research applications in lipid metabolism and disease. -
Anti-inflammatory Agent
(-)-Pinoresinol is a plant-derived tetrahydrofuran lignan that serves as an anti-inflammatory agent through the inhibition of α-glucosidase. This compound exhibits hypoglycemic properties and demonstrates chemopreventive potential by inducing apoptosis and causing G2/M phase cell cycle arrest. Its biological activities make it a valuable tool for research in inflammation and metabolic disorders. -
IDO1/TrxR1 Inhibitor
ZC0109 is a potent dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1), exhibiting IC50 values of 50 nM and 3.0 μM, respectively. This compound is effective in inducing reactive oxygen species (ROS) accumulation and causing cell cycle arrest at the G1/S phase, ultimately leading to apoptosis in cancer cells. ZC0109 is a valuable reagent for research applications focused on cancer therapy and the modulation of immune response through IDO1 and TrxR1 inhibition. -
5-Lipoxygenase Inhibitor
CNB-001 is a potent inhibitor of 5-lipoxygenase (5-LOX), demonstrating strong oral bioavailability. This compound effectively reduces 5-LOX expression and enhances proteasome activity, leading to the inhibition of soluble Amyloid-β accumulation and ubiquitinated protein aggregates. It also exhibits neuroprotective properties by inhibiting apoptosis and reactive oxygen species (ROS) production while stabilizing mitochondrial membrane potential. Additionally, CNB-001 addresses insulin resistance and enhances glucose uptake, making it valuable for research into inflammation, neurological disorders, and metabolic diseases such as Alzheimer's disease, stroke, and diabetes. -
CypA Inhibitor
HL001 is an oral small molecule inhibitor targeting Cyclophilin A (CypA) and acting as a receptor antagonist for Lysophosphatidic acid 1 (LPA1). This compound induces cell cycle arrest and apoptosis in tumor cells via p53 stabilization, achieved by down-regulating G3BP1 and promoting reactive oxygen species production and DNA damage. HL001 disrupts the MDM2-p53-72R interaction in a CypA-dependent manner, demonstrating significant antitumor activity. Additionally, HL001 serves as a valuable tool in the investigation of pulmonary fibrosis. -
PDE3A Modulator
Nauclefine is an indole alkaloid derived from Nauclea officinalis, serving as a modulator of phosphodiesterase 3A (PDE3A). This compound has been shown to promote apoptosis in cancer cells via a PDE3A-SLFN12-dependent death pathway. Its biological activity makes Nauclefine a valuable tool for research into cancer therapeutics and the understanding of apoptotic mechanisms. -
Cathepsin Inhibitor
TS-24 is a selective inhibitor of cathepsin S, demonstrating an IC50 value of 4.3 μM. This compound has been shown to exhibit radiosensitizing effects in wild-type BRCA1 and triple-negative breast cancer (TNBC) xenograft models, primarily by inducing apoptotic pathways. TS-24 is suitable for research applications focused on cancer therapeutic development and understanding cathepsin-mediated biological processes. -
α-Glucosidase Inhibitor
Malabaricone B is a naturally occurring phenolic compound that functions as an α-glucosidase inhibitor, exhibiting an IC50 of 63.7 µM. This compound demonstrates significant biological activities, including anticancer, antimicrobial, antioxidant, and antidiabetic effects. It is suitable for research applications focused on metabolic regulation and the investigation of glycemic control. -
Phospholipase A2 Inhibitor
(2E)-OBAA is a selective inhibitor of phospholipase A2 (PLA2) with an IC50 value of 70 nM. This compound effectively induces apoptosis in human umbilical vein endothelial cells (HUVECs) and demonstrates its capacity to inhibit melittin-induced Ca2+ influx in Trypanosoma brucei, exhibiting an IC50 of 0.4 μM. (2E)-OBAA is valuable for research focused on cell signaling, apoptosis, and parasitology. -
PPARγ Inhibtior
Perfluorotetradecanoic acid (PFTeDA) is a potent PPARγ inhibitor, demonstrating a binding affinity to the human PPARγ ligand-binding domain with an IC50 of 22.8 μM and a Kd of 157.8 μM. It has been shown to impair Leydig cell function through the induction of oxidative stress and apoptosis. Additionally, PFTeDA stimulates corticosterone biosynthesis while inhibiting aldosterone production, making it a valuable tool for researching steroidogenesis and related metabolic pathways. -
Phospholipase D Inhibitor
PLD-IN-1 is a selective inhibitor of phospholipase D, exhibiting an IC50 of 1.97 μM. This compound reduces the expression of immune evasion markers such as CD24, CD47, and PD-L1 while promoting calreticulin, thereby enhancing phagocytosis of lung cancer cells by macrophages. PLD-IN-1 demonstrates significant cytotoxic effects on various lung cancer cell lines, including A549, HCC44, H460, and HCC15, with IC50 values ranging from 18.44 to 24.85 μM. Additionally, it induces apoptosis, inhibits cell migration, enhances M1 macrophage polarization, and exhibits antitumor efficacy in mouse models, making it a valuable tool for cancer research. -
IDO-1/NS2B-NS3 Inhibitor
Palmatine is a selective, irreversible inhibitor of indoleamine 2,3-dioxygenase 1 (IDO-1), exhibiting IC50 values of 3 μM against HEK 293-hIDO-1 and 157 μM against rhIDO-1. Additionally, Palmatine effectively inhibits the West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. This compound demonstrates diverse biological activities including anti-cancer, anti-oxidation, anti-inflammatory, neuroprotective, antibacterial, and antiviral effects, making it a valuable tool for research in cancer biology, inflammation, and infectious diseases. -
Ahr Agonist
AHR Agonist 3 is a potent agonist of the aryl hydrocarbon receptor (AhR) that induces cell cycle arrest and apoptosis by activating tumor-suppressive transcriptional programs. It effectively inhibits the growth of stem cells in triple-negative breast cancer (TNBC) while demonstrating low cytotoxicity towards normal human primary cells. This compound is a valuable tool for cancer research, particularly in studies focused on TNBC and the mechanisms underlying AhR-mediated signaling pathways. -
Enpp/Carbonic Anhydrase Inhibitor
Enpp/Carbonic Anhydrase-IN-1 is a potent inhibitor of ecto-nucleotide triphosphate diphosphohydrolase (ENPP) and carbonic anhydrase, exhibiting IC50 values of 1.36 μM for NPP1, 1.35 μM for NPP2, 3.00 μM for NPP3, 0.88 μM for CA-II, and 1.02 μM for CA-IX. This compound demonstrates significant antiproliferative effects on cancer cells while displaying low cytotoxicity to normal cells. Additionally, Enpp/Carbonic Anhydrase-IN-1 has been shown to induce apoptosis, making it a valuable tool for cancer research and therapeutic investigations. -
Carbonic Anhydrase Inhibitor
Zonisamide sodium is a potent carbonic anhydrase inhibitor, effectively targeting hCA II and hCA V with Kis of 35.2 nM and 20.6 nM, respectively. This compound exhibits neuroprotective properties by promoting anti-apoptotic mechanisms and enhancing the expression of manganese superoxide dismutase (MnSOD). Additionally, Zonisamide sodium has been shown to upregulate Hrd1, contributing to improved cardiac function in animal models of cardiac hypertrophy. Its diverse biological activities make it suitable for investigations related to seizures, Parkinson's disease, and cardiovascular research. -
HSP90/mTOR Inhibitor
HSP90/mTOR-IN-1 is a potent inhibitor targeting both Hsp90 and mTOR, exhibiting IC50 values of 69 nM and 29 nM, respectively. This compound effectively suppresses the proliferation of SW780 cells by over-activating the PI3K/AKT/mTOR signaling pathway. In addition to inducing apoptosis and autophagy through selective inhibition, HSP90/mTOR-IN-1 demonstrates significant in vivo anti-tumor activity. It serves as a valuable reagent for research applications focused on bladder cancer. -
PAI-1 Inhibitor
TM5441 sodium is a potent inhibitor of plasminogen activator inhibitor-1 (PAI-1), demonstrating IC50 values ranging from 13.9 to 51.1 μM. It has been shown to induce intrinsic apoptosis in various human cancer cell lines, making it a valuable tool in cancer research. Additionally, TM5441 sodium mitigates cardiac hypertension and vascular senescence induced by Nω-nitro-l-arginine methyl ester, suggesting potential therapeutic applications in cardiovascular studies. -
Antitumor
3-Hydroxybakuchiol is an electron transport chain (ETC) inhibitor known for its antitumor properties. It effectively induces apoptosis in tumor cells, contributing to its potential as a therapeutic agent in cancer research. Additionally, 3-Hydroxybakuchiol exhibits moderate inhibitory activity against α-glucosidase, with an IC50 value of 345 μM, further expanding its applications in biological studies. -
Carbonic Anhydrase Inhibitor
hCAIX/XII-IN-5 is a selective inhibitor of carbonic anhydrases IX and XII, demonstrating Ki values of 93.9 nM and 85.7 nM, respectively. This compound exhibits notable anti-proliferative effects on cancer cells, leading to cell cycle delay and the induction of apoptosis. hCAIX/XII-IN-5 is a valuable tool for elucidating the roles of carbonic anhydrases in cancer biology and for developing targeted therapeutic strategies. -
PPARγ Ligand
CAY10506 is a potent ligand of peroxisome proliferator-activated receptor gamma (PPARγ) that induces cell death and reactive oxygen species (ROS) production through a PPARγ-dependent mechanism. This compound demonstrates radiosensitizing properties, enhancing apoptosis induced by gamma radiation and facilitating caspase-3-mediated cleavage of poly (ADP-ribose) polymerase (PARP). CAY10506 is applicable in cancer research, particularly in studies focused on PPARγ signaling pathways and radiation therapy augmentation. -
NAMPT Inhibitor
(E/Z)-Daporinad hydrochloride is a potent inhibitor of nicotinamide phosphoribose transferase (NAMPT). By specifically targeting NAMPT, this compound induces apoptosis through the gradual depletion of intracellular NAD+. (E/Z)-Daporinad hydrochloride is utilized in research to explore mechanisms in cancer biology and inflammatory diseases. -
IDO/Tubulin Inhibitor
IDO/Tubulin-IN-2 is a potent inhibitor targeting both indoleamine 2,3-dioxygenase (IDO) and tubulin. This compound exhibits significant anticancer activity, demonstrated by its effect on various cell lines, including U87, HepG2, A549, HCT-116, and LO2, with IC50 values of 0.43, 0.036, 0.041, 0.095, and 1.04 μM, respectively. IDO/Tubulin-IN-2 is valuable for research applications in cancer biology, particularly in elucidating mechanisms of tumorigenesis and therapeutic resistance. -
PDE1 Inhibitor
PDE1-IN-6 is a selective phosphodiesterase 1 (PDE1) inhibitor with an IC50 of 7.5 nM. It effectively inhibits cell proliferation and induces apoptosis in acute myelogenous leukemia (AML) cells. This compound serves as a valuable tool in cancer research, particularly in studies focused on signaling pathways involved in leukemia progression and treatment. -
PKM2 Inhibitor
MTP is a potent inhibitor of pyruvate kinase M2 (PKM2) that induces apoptosis in cancer cells through the modulation of caspase-3 activation. Additionally, MTP promotes autophagy and enhances reactive oxygen species (ROS) generation, while also inhibiting JAK2 signaling pathways. This compound is particularly valuable for research applications focused on oral squamous cell carcinoma and related cancer studies. -
TrxR Inhibitor
PAO-Nap is a selective thioredoxin reductase (TrxR) inhibitor modified with a naphthalimide fluorophore linked via aminocaproic acid. This compound induces oxidative stress-mediated apoptosis in HL-60 cells, making it a valuable tool for studying apoptotic pathways and oxidative stress mechanisms in cancer research. Its unique fluorescent properties also facilitate real-time monitoring of cellular responses to TrxR inhibition. -
PDE6/NAMPT Inhibitor
PDEδ/NAMPT IN-1 is a potent dual inhibitor targeting phosphodiesterase 6 (PDE6) with a binding affinity of 0.410 nM and nicotinamide phosphoribosyl transferase (NAMPT) with an IC50 of 2.21 nM. This compound effectively disrupts KRAS-related signaling pathways and hampers the synthesis of nicotinamide adenine dinucleotide (NAD+), leading to apoptosis in KRAS mutant pancreatic cancer cells. PDEδ/NAMPT IN-1 holds significant potential for advancing research in KRAS mutant pancreatic cancer. -
Monoamine Oxidase Inhibitor
Harmol hydrochloride is a potent monoamine oxidase inhibitor that functions as a transcription factor EB (TFEB) activator. It demonstrates significant biological activities, including the induction of cell mitosis, autophagy, and apoptosis. Additionally, Harmol hydrochloride promotes the degradation of α-synuclein by modulating the autophagy-lysosomal pathway, making it relevant in studies of neurodegenerative diseases. Its diverse pharmacological effects also extend to anti-tumor, anti-depressant, and anti-aging activities, and it has shown promise in alleviating motor impairments in models of Parkinson's disease. -
Drug Metabolite
3-O-Methyltolcapone is a drug metabolite derived from Tolcapone, a selective and potent inhibitor of catechol-O-methyltransferase (COMT) with an IC50 of 773 nM. This compound is known to block α-synuclein and Aβ42 oligomerization and fibrillogenesis, while also inducing oxidative stress, apoptosis in cancer cells, and reactive oxygen species (ROS) production. Research applications include studies related to cancer and neurological disorders, particularly in the context of Parkinson’s disease and neuroblastoma. -
Cathepsin B/CANP Inhibitor
NCO-700 is a potent dual inhibitor of cathepsin B and calcium-activated neutral protease (CANP), exhibiting IC50 values of 0.8 μM and 46 μM, respectively. This compound effectively reduces myocardial fibrin degradation by inhibiting protease activity and demonstrates significant anti-tumor effects on hormone-independent cancer cells, including prostate cancer, by inducing apoptosis. NCO-700 serves as a valuable tool for investigating mechanisms underlying myocardial ischemia and exploring novel treatments for refractory hormone-independent tumors. -
IDO1/TrxR Inhibitor
ZC0101 is a potent dual inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase (TrxR), exhibiting IC50 values of 0.084 μM and 7.98 μM, respectively. This compound demonstrates significant biological activity by inducing apoptosis and promoting reactive oxygen species (ROS) accumulation in cancer cells. ZC0101 is a valuable tool for research applications aimed at understanding cancer cell metabolism and exploring therapeutic strategies targeting IDO1 and TrxR pathways.
